PWA
AZN icon

Providence Wealth Advisors’s AstraZeneca AZN Stock Holding History

Providence Wealth Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$246K Sell
1,226
-7
-0.6% -$1.35K 0.16% 71
2025
Q4 		$224K Sell
1,233
-309
-20% -$54.2K 0.14% 75
2025
Q3 		$255K Sell
1,542
-337
-18% -$51K 0.16% 70
2025
Q2 		$279K Buy
+1,879
New +$263K 0.19% 67

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Providence Wealth Advisors's AZN Position: Q1 2026 in Review

Providence Wealth Advisors reduced its AstraZeneca (AZN) stake by 0.57% in Q1 2026, selling an estimated $1.35K and leaving 1,226 shares worth $246K. The position accounts for 0.16% of the portfolio, ranked #71.

Providence Wealth Advisors first reported a position in AZN in Q2 2025 and has held it in 4 quarters since. The position peaked at $279K in Q2 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Providence Wealth Advisors held 1,226 shares of AstraZeneca worth $246K as of Q1 2026.
  • Providence Wealth Advisors sold 7 AstraZeneca shares in Q1 2026, an estimated $1.35K.
  • AstraZeneca made up 0.16% of Providence Wealth Advisors's portfolio in Q1 2026, its #71 holding.
  • Providence Wealth Advisors first reported a position in AstraZeneca in Q2 2025 and has held it in 4 quarters since.
  • Providence Wealth Advisors's AstraZeneca position peaked at $279K in Q2 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Providence Wealth Advisors's 13F filing for Q1 2026, filed 5 May 2026.